Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat cancers? early trial of HRO761 begins

NCT ID NCT05838768

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 21 times

Summary

This study tests a new drug called HRO761, alone or combined with other treatments, in people with advanced solid tumors that have specific genetic markers (MSI-high or dMMR). The main goals are to find safe and effective doses and to see how well the drug shrinks tumors. About 123 participants whose cancer has worsened after standard therapy will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia University Medical Ctr

    New York, New York, 10032, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Memorial Sloan Kettering

    New York, New York, 10017, United States

  • Novartis Investigative Site

    Brussels, 1200, Belgium

  • Novartis Investigative Site

    Beijing, 100036, China

  • Novartis Investigative Site

    Guangzhou, 510655, China

  • Novartis Investigative Site

    Bordeaux, 33076, France

  • Novartis Investigative Site

    Marseille, 13273, France

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    Milan, MI, 20162, Italy

  • Novartis Investigative Site

    Rozzano, MI, 20089, Italy

  • Novartis Investigative Site

    Kashiwa, Chiba, 2778577, Japan

  • Novartis Investigative Site

    Oslo, 0310, Norway

  • Novartis Investigative Site

    Singapore, 119228, Singapore

  • Novartis Investigative Site

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    Madrid, 28009, Spain

  • Novartis Investigative Site

    Madrid, 28040, Spain

  • Novartis Investigative Site

    Valencia, 46010, Spain

  • Novartis Investigative Site

    Stockholm, 17176, Sweden

  • Novartis Investigative Site

    Taipei, 10002, Taiwan

  • Novartis Investigative Site

    London, SW3 6JJ, United Kingdom

  • Novartis Investigative Site

    Oxford, OX3 7LE, United Kingdom

  • UCSF

    San Francisco, California, 94115, United States

  • Univ of TX MD Anderson Cancer Cntr

    Houston, Texas, 77030, United States

  • University of California LA

    Los Angeles, California, 90095, United States

Conditions

Explore the condition pages connected to this study.

MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS